Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H25N8O11S2.Na |
Molecular Weight | 712.643 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[H][C@]12SCC(\C=C3/CCN([C@@H]4CCN(C4)C(=O)OCC5=C(C)OC(=O)O5)C3=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C6=NSC(N)=N6)C([O-])=O
InChI
InChIKey=MFAWUGGPPMTWPU-LCJFHXTKSA-M
InChI=1S/C26H26N8O11S2.Na/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18;/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31);/q;+1/p-1/b11-6+,30-15-;/t13-,16-,22-;/m1./s1
Ceftobiprole is a fifth-generation cephalosporin antibiotic. It was discovered by Basilea Pharmaceutica and was developed by Johnson & Johnson Pharmaceutical Research and Development. The drug is demonstrates activity against clinically important gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, penicilliin-resistant Staphylococcus pneumoniae, and Enterococcus faecalis. The drug also has demonstrated activity against gram-negative bacteria including Citrobacter spp., Escherichia coli, Enterobacter spp., Klebsiella spp., Serratia marcescens, and Pseudomonas aeruginosa. The drug has gained regulatory authorization from European states for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25117196 |
|||
Target ID: CHEMBL3512 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16922591 |
PubMed
Title | Date | PubMed |
---|---|---|
Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. | 2008 Jan |
|
Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). | 2010 Nov |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J01DI01
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
||
|
WHO-VATC |
QJ01DI01
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
ZEFTERA (REFUSED SOFT TISSUE INFECTIONS)
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB14733
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
SUB130376
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
SS-13
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
252188-71-9
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
100000156073
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
DTXSID601021562
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
N99027V28J
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
4402
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL1652606
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
m3223
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
C70597
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
135413543
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD